A Phase 3 Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Daily Subcutaneous Injections of Elamipretide in Subjects With Primary Mitochondrial Myopathy Followed by an Open-Label Treatment Extension

Trial Profile

A Phase 3 Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Daily Subcutaneous Injections of Elamipretide in Subjects With Primary Mitochondrial Myopathy Followed by an Open-Label Treatment Extension

Recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Apr 2018

At a glance

  • Drugs Elamipretide (Primary)
  • Indications Mitochondrial myopathies
  • Focus Registrational; Therapeutic Use
  • Acronyms MMPOWER-3
  • Sponsors Stealth BioTherapeutics
  • Most Recent Events

    • 06 Nov 2017 According to a Stealth Biotech media release, this study will enroll eligible patients who previously participated in RePOWER, an ongoing, prospective, non-interventional study evaluating patients with PMM.
    • 06 Nov 2017 Status changed from not yet recruiting to recruiting according to a Stealth BioTherapeutics media release.
    • 23 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top